Dr. Stephen Liu and Dr. Narjust Duma host Lung Cancer Considered, the podcast of The International Association for the Study of Lung Cancer (IASLC). IASLC is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 6,500 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit www.iaslc.org for more information.
Lung Cancer considered is funded in part by AstraZeneca, Bristol Myers Squibb, Lilly Oncology, and Merck KGaA.
Finding Your First Job With Mark Awad Jyoti Patel And Ana Velazquez Manana
Career transitions are normal in academic oncology, oncology practice, and industry and today's oncologists go through a number of 'job' interviews during their post-graduate life and early career. In this episode of Lung Cancer Considered, host Dr. Narjust Florez discusses how to find or transition to that new job in thoracic oncology. Joining the discussion are three lung cancer researchers:
Dr. Mark Awad, clinical director of the Thoracic Oncology Group at Dana Farber Cancer Institute, assistant professor of Medicine at Harvard Medical School and a leading researcher in KRAS-mutant NSCLC.
Dr. Ana Velazquez, instructor of medicine and thoracic medical oncologist at UCSF and a postdoctoral fellow at the National Clinical Scholars Program. Dr. Velazquez is completing her training and searching for her faculty position.
Dr. Jyoti Patel, associate vice for clinical research, a thoracic medical oncologist, and professor of medicine at Northwestern University in Chicago. Dr. Patel is a leader in thoracic oncology, focusing her efforts on the development and evaluation of novel molecular markers and therapeutics for patients with non-small cell lung cancer.
Mesothelioma With Melina Marmarelis And Sanjay Popat
Treatment for malignant pleural mesothelioma has undergone dramatic shifts in the past few years. To discuss these changes and the research behind them, Lung Cancer Considered Host Dr. Stephen Liu welcomes Dr. Sanjay Popat and Dr. Melina Marmarelis. Dr. Popat is a Consultant Thoracic Medical Oncologist at The Royal Marsden and Professor of Thoracic Oncology at the Institute of Cancer Research, in London, England, and Chair of the British Thoracic Oncology Group. He is also on the Board of Directors for the Mesothelioma Applied Research Foundation. Dr. Marmarelis is an Assistant Professor of Medicine at the Hospital of the University of Pennsylvania and the Medical Director of the Penn Mesothelioma and Pleural Program.
Virtual Tumor Board PDL1 Negative NSCLC With Reyes Bernabé And Hoss Borghaei
In this episode of Lung Cancer Considered, host Dr. Stephen Liu leads a discussion on the management of metastatic, PDL1 negative NSCLC. He is joined by Dr. Hossein Borghaei and Dr. Reyes Bernabe Caro.
Dr. Borghaei is a professor and Chief of Thoracic Oncology at Fox Chase Cancer Center in Philadelphia. He was the lead author for CheckMate 057, was involved in many of the landmark immunotherapy trials, and is the national PI for the ongoing INSIGNA trial. Dr. Reyes Bernabe Caro is the Section Chief of Medical Oncology and Head of the Thoracic Tumor Unite at the Hospital Universitario Virgen Rocio in Seville, Spain. She also has extensive experience in immunotherapy combinations and is an author on the NADIM and CheckMate 227 studies.
Trastuzumab - Deruxtecan (T-DXd) With Lyudmila Bazhenova And Julien Mazieres
On the heels of accelerated approval by the US FDA, Dr. Stephen Liu discusses trastuzumab-deruxtecan (T-DXd) with medical oncologists and clinical investigators, Dr. Lyudmila Bazhenova, from the University of California, San Diego, and Dr. Julian Mazieres, from Toulouse University Hospital. T-DXd is an antibody-drug conjugate now approved for the treatment of HER2-mutant NSCLC, and in this episode, its design, efficacy, and safety are reviewed.
WCLC 2022 Wrap Up
It’s a wrap! Catch up on key highlights of the IASLC 2022 World Conference on Lung Cancer with Dr. Narjust Florez and Dr. Stephen Liu as they discuss the science, social engagement and notable abstracts with Dr. Ben Levy.
WCLC 2022 Daily Highlights - August 9
We’ve approached a remarkable close to the last day of the IASLC 2022 World Conference on Lung Cancer in Vienna, Austria. Lung Cancer Considered hosts Dr. Stephen Liu and Dr. Narjust Florez interview Dr. Belinda King Kallimanis, Dr. Charles Rudin and Dr. Solange Peters about patient-centric clinical trial consent forms, an update on the Keynote 604 trial, the importance of women’s sexual health and new data on a combination of therapies for patients with KRAS mutations.
Episode on Immunotherapy
Really enjoyed the conversation between these oncologist. They seem to be great doctors who really care for their patients are working for the best solutions they know of.
It was also interesting to see their blind spots. The great thing about immunotherapy is slowly opening the door between integrative oncology and traditional oncology. These guys don’t get into it but they are asking the right questions.
1) What can be combined with immunotherapy?
2) What can be done to prevent side effects of traditional treatment?
3) What things can be done to both enhance traditional treatments and lower side effects?
Naturopath and integrative doctors know many possible answer to these questions based on case studies and their personal experience. Things that will never get a $500 million dollar set of clinical trials, but have worked for patient after patient.
- Infrared Saunas to detox from chemo and have much fewer side effects (combined with other detox techniques).
- High Dose Melatonin to reduce radiation damage - with early limited clinical trials as evidence.
- Hypothermia for combining with immunotherapy.
- Proton radiation on a different schedule than normal to promote immunotherapy (3 day on 4 day off cycle seems to work better than the traditional 5 day on 2 day off, to give the immune system a chance to do its thing).
- Micro-biome research to enhance immunotherapy both through diet, supplements, and even fecal transplants.
- Natural products and off-label drugs to help limit the metabolism of cancer to slow down its growth, keep it from mutating to new food sources, and ultimately make chemo and other treatments more effective, as well as providing a much greater quality of life for the patients.
If transitional oncology would do two things, immunotherapy will advance much faster.
1) Eat a bite of humble pie and realize integrative doctors and oncologist have some answers, and start having conversations with them.
2) Realize their training and education failed them in the areas of nutrition, health, and epi-genetics.
3) Realize the level of corruption in the FDA, NIH, and pharmaceutical companies, with at least 350 MILLION dollars being passed under the table to individual for the last 10 years. This seems to be greatly hampering the rules being used to approve new drugs - creating measure that have nothing to do with patient survival - but do help big pharma profits. So after realizing there is this level of corruption and unethical behavior, it is illogical and unethical to continue to just rely on these groups to produce the “cures” for cancer.
It is going to take people doing and trying things have have more ethical motivations, writing papers, doing smaller trials, and forcing innovation solutions down the throat of the FDA with them kicking an screaming.
Then someone needs to do something to STOP the unethical price gouging of the Pharma on immunotherapy. The are obviously coordinating their pricing in a cornered market. Again unethical and unjustified. We need to vote for political leaders who can pass some laws to bring this into account.
And all the Cancer patient advocacy groups that are SILENT on these issues need to be shamed into action… even though they get big donations from big Pharma too.
Fantastic for doctors, nurses, patients
Great conversations on all things lung cancer.